ATP-binding-cassette (ABC) transporters are evolutionary extremely well-conserved transmembrane proteins that are highly expressed in hematopoietic stem cells (HSCs). The physiological function in human stem cells is believed to be protection against genetic damage caused by both environmental and naturally occurring xenobiotics. Additionally, ABC transporters have been implicated in the maintenance of quiescence and cell fate decisions of stem cells. These physiological roles suggest a potential role in the pathogenesis and biology of stem cell-derived hematological malignancies such as acute and chronic myeloid leukemia. This paper reviews the (patho)physiological role of ABC transporters in human normal and malignant HSCs and discusses its implications for their utility as therapeutical targets to eradicate leukemic stem cells in these diseases.
Introduction
The ATP-binding-cassette (ABC) transporters are evolutionary and extremely well-conserved transmembrane proteins involved in the transmembrane transport of a huge variety of substrates including sugars, peptides, inorganic anions, amino acids, oligopeptides, polysaccharides, proteins, vitamins and metallic ions. 1, 2 The human superfamily of ABC transporters represents the largest family of transmembrane proteins, currently consisting of 49 members. The genes can be divided into subfamilies based on similarity in gene structure resulting in seven mammalian ABC gene subfamilies (ABCA, B, C, D, E, F and G family).
The most widely studied members ABCB1 (MDR1/P-glycoprotein), ABCC1 (multidrug resistance protein, MRP1) and ABCG2 (breast cancer resistance protein, BCRP) have the ability to export a wide variety of structurally unrelated chemotherapeutical compounds from cancer cells, thereby conferring multidrug resistance (MDR) to these cells. 3 There are many excellent reviews on ABC transporters in the literature among which are those referred to in this review. The current review will focus on the expression and physiological function of these proteins in normal and leukemic hematopoietic stem cells (HSCs) and the implications for the biology and treatment of acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).
ABC transporters in hematopoietic stem cells

ABC transporter activity as marker of hematopoietic stem cells
Human (hematopoietic) stem cells are characterized by their ability to efflux fluorescent dyes. Isolation of stem cells based on this efflux is an efficient method to purify stem cells from different sources. It has been demonstrated that retention of rhodamine-123 is low in the most primitive hematopoietic cells. 4, 5 While the rhodamine-123-dull fraction provides longterm reconstitution following injection into lethally irradiated mice, the rhodamine-123-bright fraction provides only shortterm repopulation. 5, 6 Hoechst 33342 is another fluorescent dye used for the isolation of a stem cell-enriched fraction, called the side -population (SP). 7, 8 In combination with rhodamine-123 staining, Hoechst 33342-dull/rhodamine-123-dull cells are highly enriched for stem cell function. 9 Murine HSCs defined by long-term multilineage repopulation assays efflux both the dyes variably according to their developmental or activation status. 10 The molecular basis of this phenotype has long been unclear, but recent studies indicate that ABC transmembrane transporters that efflux the fluorescent dyes are responsible for the dull phenotype of HSCs. ABCB1 is highly expressed on CD34 þ hematopoietic cells suggesting that efflux pump activity could be responsible for the low retention of rhodamine-123 in primitive cells. 11 Studies in knock-out mice have indeed shown that ABCB1 is the main determinant of the rhodamine-dull phenotype of HSCs. [12] [13] [14] Recently, BCRP has been shown to be highly expressed in a wide variety of stem cells 15 including immature human hematopoietic progenitors 16 and confer the SP phenotype. Although both ABCB1 and ABCG2 have the capacity to extrude Hoechst 33342, it has been established that the SP phenotype of HSCs in mice is mainly conferred by the ABCG2 transporter. 17 Physiological function of ABC transporters in HSCs: Role in protection against toxic substrates. Although ABC-transporter-mediated dye extrusion has been a very efficient way of enriching stem cells of many sources for many years, the functional significance of ABC transporters for HSC biology remains largely elusive. A role of ABC transporters in the protection from genetic damage by naturally occurring xenobiotics that are substrates for the transporter has been suggested for HSCs 11, 18 and substantiated by the observation of increased cytotoxicity to bone marrow in ABCG2/BCRP knock-out mice. 17 The relative protective effect of ABCG2 of HSC was shown elegantly in this study using competitive repopulation assays comparing transplanted ABCG2À/À to wild-type cells. This protective effect was confirmed in a knock-out primate model, 19 although this study did not address cytotoxicity of HSC but rather CD34 þ progenitor cells in an in vitro survival assay. Formally, the protective effect of ABCB1 in HSC has been less firmly established because studies have addressed hematopoietic progenitor cells rather than HSC. It is, however, reasonable to assume, given the preferential expression of ABCB1 in HSC in comparison to CD34 þ 38 þ progenitor cells 20 that ABCB1 exerts its most pronounced cytoprotective effect in HSC.
The role of ABCC1 in the protection of bone marrow against chemotherapeutical compounds was initially studied in MRPÀ/À knock-out mouse showing increased sensitivity to vincristine as suggested by a delayed recovery of white blood cells and bone marrow histology. 21 Similar observations were made in chimeras of wild-type mice transplanted with bone marrow ABCC1 (MRP)À/À, ABCB1 (MDR1a and -b) doubleÀ/À or ABCC1/ABCB1 tripleÀ/À donor mice, 22 excluding the pharmacokinetic effect of reduced drug clearance in MRPÀ/À mice.
Although the experimental design of these studies (in vitro toxicity of CFU and determination of WBC at day 2 after injection) assessed the protective effect on the progenitor CD34 þ population rather than the HSC population, the data firmly support a role of ABC transporters in the protection of hematopoietic progenitor and stem cells to the effect of xenobiotics, with ABCB1 and ABCG2 being presumably the most dominant transporters in HSC. It has to be noted, however, that the highly conserved homology between different ABC transporters predicts that additional members may be involved in the extrusion of xenobiotic and chemotherapeutical compounds. Indeed, an increasing number of ABC transporters have been demonstrated to cause resistance to cancer chemotherapeutical agents 23, 24 (Table 1) . In a recent gene expression profiling study revealing the expression profile of all ABC transporters in human CD34 þ CD38À HSC, all of these transporters were found to be expressed in human CD34 þ 38À hematopoietic cells of which most in a differential manner in comparison to committed CD34 þ 38 þ cells. 25 Additionally, recent studies examining ABC transporter gene expression in drug-selected cancer cell lines demonstrated overexpression of  a number of transporters not previously recognized as associated  with drug resistance (ABCA4, ABCA7, ABCB2, ABCB6, ABCB8,  ABCB9 and ABCG1) . 26 With the exception of ABCC4, all these transporters are expressed in human CD34 þ 38À hematopoietic cells, again many differentially in comparison to committed progenitors. Together, these data outline the emerging picture that ABC-transporter-mediated protection against xenobiotics and other toxic substrates may be conferred by simultaneous activity of many redundant family members in addition to ABCB1, ABCC1 and ABCG2. The definitive role of these transporters in the protection of HSC remains to be determined.
Role in cell quiescence, differentiation and self-renewal.
ABC transporters are evolutionary extremely well conserved between species suggesting that they are key molecules in fundamental physiological processes. Recent gene expression profiling of all ABC transporters in stem cells from different sources (embryonic, mesenchymal and hematopoietic; unpublished results) demonstrates the presence of a large, partly overlapping, number of transporters on all stem cell sources. The presence of many ABC transporters with a wide variety of putative substrates in (hematopoietic) stem cells predicts that, in addition to the protection of these long-lived cells against naturally occurring xenobiotics, they are involved in processes that are essential or the stem cell character of these cells. A first glimpse into their putative physiological significance in these cells has come from studies in Dictyostelium demonstrating that a rhodamine-123 cellular efflux pump (RhT) with the properties of an ABC transporter prevents differentiation of prespore cells, 27 possibly by exporting differentiating factors from the cell interior. This led to the hypothesis that a cell's response to a signal that can diffuse across the plasma membrane depends, in part, on the cell's ability to remove it from the cytoplasm. According to this hypothesis, ABC transporters may help HSCs escape the effect of differentiation factors present in the bone marrow regulating the cellular concentration of signaling and cell fate decisions. However, so far no such role has been conclusively demonstrated for the ABC transporters identified on human (hematopoietic) stem cells as detailed in the next section.
Role of ABCB1, ABCC1 and ABCG2 in stem cell biology and hematopoiesis. Retroviral-induced overexpression of ABCB1 resulted in increased hematopoietic repopulating activity and myeloproliferative disease in mice. [28] [29] [30] However, when extrapolating these experiments to a primate model using competitive repopulation assays and long-term follow-up of hematopoiesis, no detectable adverse consequences have been observed. 31, 32 In line with this, MDR1 induction in hematopoietic cells in clinical trials, in an attempt to protect these cells for chemotherapeutical damage, has not resulted in abnormal hematopoiesis 33, 34 and marrow of adult mdr1a/1bÀ/À mice shows normal generation, function and multi-tissue trafficking of primitive hematopoietic cells.
14 Together these studies failed to demonstrate a role for ABCB1 in steady-state hematopoiesis.
In contrast to the expansion phenotype of ABCB1 overexpression studies in the murine model, overexpression of BCRP/ABCG2 in a mouse model significantly blocked hemato- poietic development and resulted in reduced engraftment of HSC (resulting in less progeny in the bone marrow and peripheral blood) when tested in in vivo competitive repopulation assays. 15 These results suggested that ABCG2 may play a role in stem cell engraftment potential, but subsequent overexpression of ABCG2 in primate bone marrow cells did not interfere with HSC maturation and engraftment potential in vivo (in competitive assays). 19 The reason for the lack of hematopoietic overexpression phenotypes in primates in comparison to murine models is not entirely clear but may be explained by differences in gene transfer efficiency in HSCs (increased vector insertion sites in mice versus primate HSC) or point in the direction of redundancies in the more complex primate hematopoiesis. The wide expression of many members of different ABC transporters in human HSCs in combination with their known structural similarities would support the latter view.
Similar to the lack of hematopoietic abnormalities in ABCB1À/À mice, ABCG2À/À null mice display no defects in steady-state hematopoiesis. Competitive repopulation assays with ABCG2 wild-type and À/À bone marrow cells revealed no differences in stem cell activities. In this model, although ABCG2 expression was required for the SP phenotype, repopulating HSCs are maintained outside the SP region 17 in line with a recent study identifying CD34-c-kit þ sca-1 þ linrepopulating cells with comparable characteristics including ABCG2 expression inside and outside the SP, arguing that the functional efflux phenotype is not required for stem cell characteristics of these cells. 35 Finally, experiments using ABCB1/ABCG2 double knock-out mice confirmed a lack of effect on hematopoiesis, excluding possible redundant activity of these transporters. 36 It has to be noted, however, that none of the studies in knock-out mice included the investigation of the self-renewal capacity of ABCB1/ABCG2À/À hematopoietic cells (by testing the potential of these cells to engraft secondary recipients). The effect of these ABC transporters on this key characteristic of HSC remains therefore poorly addressed.
Recently, a role of ABCC1 in the differentiation of dendritic cells was suggested using (pleiotropic) inhibitors of ABCC1 function. 37 Similarly, ABCC1 was implicated in the differentiation of a thymoma cell line into CD4 þ CD8 þ cells. 38 Although these studies failed to identify the involved substrates and ABCC1 was not targeted by more specific molecular means, in both these reports it is hypothesized that ABCC1 is important to keep cells in an undifferentiated state, reiterating the possibility that ABC transporters may play a role in the differentiation of mature bone marrow cell types. Whether ABCC1 has such a role in HSC remains to be determined. The protein is preferentially expressed and functionally active in human CD34 þ 38À HSCs, 20, 39 but studies in ABCC1 (MRP1)À/À knock-out mice 40, 41 did not show abnormal hematological parameters. Critical assays on HSC functioning such as engraftment (in competitive repopulation assays) and self-renewal capacity (using secondary recipient transplantation assays), however, have not been reported in these studies.
Taken together, although the roles of ABCB1, ABCG2 and ABCC1 in hematopoiesis remain to be fully elucidated, the current knowledge does not support a role for these transporters in steady-state hematopoiesis but rather a role in protecting stem cells from genetic damage of naturally occurring xenobiotics that are the substrate for these transporters. 18 This seems particularly important for HSCs, given their life-long presence in the bone marrow and high proliferative activity during this period. In this context, it is noteworthy that an anti-apoptotic role for ABCB1 has been demonstrated recently promoting cell survival by inhibiting caspase activation.
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Physiological function of other ABC transporters in HSC. Characterization of molecules with tightly controlled expression patterns during differentiation represents an important approach to understanding the regulation of HSC commitment. ABC transporter gene expression profiling identified a large number of ABC transporter genes that displayed differential expression in human hematopoietic CD34 þ 38À stem cells of which many have not previously been associated with stem cell biology. 25 In this study ABCB7 was found among the ranking order top 5 of genes with the highest gene expression in human HSC (ABCC1, ABCA2, ABCB7, ABCB1 and ABCB2). ABCB7 is the human orthologue of the yeast mitochondrial ABC transporter ATM1p, which has been implicated in the transport of a substrate required for the maturation of cytosolic iron-sulfur cluster proteins out of mitochondria. Missense mutations in human ABCB7 have been found in patients with X-linked sideroblastic anemia with ataxia (XLSA/A). Recently, it was formally shown that XLSA/A is due to partial loss of functional ABCB7 alleles. 46 Strikingly, using a conditionally targeted allele of abcb7 bred to the interferon alpha inducible Mx1-Cre line, gene deletion of abcb7 led to severe pancytopenia and markedly hypocellular bone marrow with a median survival of mice of 16 days. No gross or microscopic abnormalities in other tissues were found at that time despite partial or near complete loss of the abcb7 gene in many tissues. From point mutation alleles corresponding to mutations found in humans with XLSA/ A, the authors concluded that XLSA/A anemia is due to partial loss of abcb7 function alleles, but the striking finding was that the deletion of a single ABC transporter ablates hematopoiesis in mice showing that ABCB7 is essential for murine hematopoiesis. Future studies will have to address the physiological processes conferred by abcb7 in HSC elucidating the exact mechanisms by which ablation of this gene leads to this striking phenotype.
Interestingly, among the ranking order of the 10 ABC transporters in HSC, 25 five members of the ABCA family are listed (that is, ABCA5, ABCA6, ABCA9, ABCA10 and ABCA13). Four of these genes (that is, ABCA5, ABCA6, ABCA9 and ABCA10) are arranged in a cluster on chromosome 17q24 representing a phylogenetically distinct subgroup within the ABCA gene subfamily. 47, 48 Recent studies have led to the concept that transporters of the ABCA subclass serve critical physiological functions in the transmembrane transport of endogenous lipid substrates. For example the prototypic member of the ABCA subfamily ABCA1 has been shown to be a major regulator of HDL metabolism that functions as a facilitator of cellular phospholipid and cholesterol export. Recently, the subgroup of ABCA genes mapping to human chromosome 17q24.2-3 has been cloned in human macrophages. Though their substrates and function are unknown, their expression has been shown to respond to lipid loading in macrophages, indicating that these transporters may serve critical physiological functions in the transmembrane transport of endogenous lipid substrates such as phospholipids and essential fatty acids, substrates involved in the regulation of differentiation of hematopoietic cells (reviewed in Rizzo MT 49 ). The finding that in addition to ABCA phospholipid transporters, ABCG1 is differentially expressed in HSCs, 25, 50 a protein that regulates phospholipid transport further suggests that ABC transporters may be critically involved in the homeostasis of phospholipids and fatty acids in HSC, and thus in cell fate decisions in HSCs. Clearly, further research is warranted to elucidate the role of these ABCA transporters in stem cell biology. The emerging picture of the role of ABC transporters in stem cell biology predicts that the current knowledge is only at the very early stages. Future investigations of transporters differentially expressed in HSC are likely to identify transporters directly involved in HSC characteristics such as engraftment and self-renewal potential. ABC transporters governing cell quiescence and differentiation, potentially by the regulation of intracellular concentrations of differentiating agents, much like in Dictyostelium, are predicted to be identified in this process.
Unraveling the mechanisms and substrates by such transporters that confer their action would greatly contribute to the understanding of stem cell biology in general and hematopoiesis in particular.
ATP-binding
cassette transporters in leukemic stem cells and their implications for the biology and treatment of acute and chronic myeloid leukemia
Myeloid leukemia as a hematopoietic stem cell disease
In recent years it has become evident that AML is organized as a hierarchy similar to normal hematopoiesis with leukemic stem cells residing within the CD34 þ 38À cell population. Evidence for the existence for a leukemic stem cell in AML has come from the studies using the nonobese diabetic/severe combined immunodeficient mice mouse model showing that cells with leukemic stem cell characteristics, defined as capacity for engraftment and self-renewal potential, are present in AML. 51, 52 Leukemic stem cells were found within the CD34 þ 38À cell population in most cases of AML and not in CD34 þ 38 þ progenitors. Although committed progenitors or even differentiated cells may also become leukemia-initiating cells through the activation of oncogenic pathways that reestablish stem cell (self-renewal) capacities, [53] [54] [55] these studies stress that leukemiainitiating transformation and progression-associated genetic events occur at the level of primitive CD34 þ 38À cells in most cases of AML. A similar role for the CD34 þ CD38À compartment in leukemogenesis has been suggested for CML, acute lymphoblastic leukemia and the myelodysplastic syndrome.
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Therapeutical implications of AML as a stem cell disease
The recognition of AML and other forms of cancer as diseases originating from normal stem cells dictates a paradigm shift in the treatment of leukemia away from targeting the blast cells and toward targeting the leukemic stem cell. Therapies directed against mature leukemic cells may produce clinical improvement and responses but are unlikely to be curative if leukemic stem cells that are responsible for maintenance of the disease are not targeted or are resistant to therapy. The high expression of ABC transporters involved in the extrusion of chemotherapeutical compounds on normal HSCs could thus be a major mechanism of drug resistance to these cells and prevent chemotherapeutical eradication of this tumor-initiating cell population. 59 Of note, although generally considered to be limited to the CD34 þ 38À cell population, leukemic stem cells have also been detected in CD34À SP þ cells 60 and these cells also displayed intrinsic mitoxantrone and daunorubicin efflux capacity. In the treatment of leukemia, ABC drug transport inhibitors might thus be thought of as 'leukemia stem cellsensitizing agents' that allow the destruction of the most crucial and drug-resistant cells in the leukemia hierarchy. To support this, it would be important to know whether expression and function of ABC transporter is conserved after malignant transformation of hematopoietic CD34 þ 38À stem cells and whether its modulation targets leukemic stem cells, focusing on ABCB1 and ABCG2 as the main xenobiotic and chemotherapeutical effluxing proteins in normal HSC.
ABCB1 and ABCG2 in drug resistance of AML CD34 þ 38À hematopoietic cells
Although ABCB1 and ABCG2 have been widely studied in AML, there is a remarkable paucity of studies addressing their role in drug efflux and chemoresistance of leukemic CD34 þ 38À cells. Expression and function of ABCB1 was recently studied in CD34 þ 38À cells in AML in comparison to their counterparts in human normal bone marrow. 61 These investigations confirmed that ABCB1 is the major molecular determinant of the mitoxantrone and rhodamine-123 'dull' phenotype of CD34 þ 38À cells in normal bone marrow as evidenced by the blockage of transport of these compounds by ABCB1 inhibitors verapamil and PSC-833. Surprisingly, ABCB1-mediated transport was invariably reduced in the leukemic CD34 þ 38À cells in comparison to their normal counterparts regardless of disease subtype. Importantly, ABCB1 modulation abrogated mitoxantrone efflux in normal but not leukemic CD34 þ 38À cells due to activity of additional drug transporters in leukemic cells. ABCB1 efflux capacity identified a subpopulation with residual normal CD34 þ 38À cells. Interestingly it has been reported that the capacity to efflux Hoechst 33342 (SP) identifies a subpopulation of CD34 þ 38À residual normal cells in AML, whereas CD34 þ 38À Hoechst bright cells were leukemic. 62 Although these authors could not relate Hoechst 33342 efflux with ABCB1 protein expression in the overall SP of cells, this was not investigated in the CD34 þ 38À subset. Moreover, recent gene expression studies revealed significantly lower levels of ABCB1 transcripts in CD34 þ 38À cells in AML in comparison to normal bone marrow. 25, 50 The combined in vitro data suggest that leukemic CD34 þ 38À cells escape the effect of ABCB1 modulation through the action of redundant mechanisms which could provide an alternative explanation for the poor results of ABCB1 modulation on long-term disease outcome in clinical trials. 63, 64 In elucidating the role of ABCG2 in the redundant mitoxantrone efflux, it was found that ABCG2 is preferentially expressed in leukemic CD34 þ 38À stem cells and contributes to mitoxantrone efflux in these cells. 65, 66 ABCG2 expression and efflux in leukemic CD34 þ 38À cells are not different from expression and function in normal CD34 þ 38À cells, thus reflecting a conserved physiological function of ABCG2 in primitive hematopoietic cells rather than being a leukemiaassociated phenotype. Selective blockage of ABCG2-mediated drug extrusion by the novel fumitremorgin (FTC) C analogue KO143, the most potent ABCG2 inhibitor currently available, 67 resulted in increased intracellular mitoxantrone accumulation in leukemic CD34 þ 38À cells in most patients but did not increase chemosensitivity of these cells to this agent. 65 This lack of a chemosensitizing effect of ABCG2 modulation by KO143 was anticipated by the observation of substantial drug efflux in leukemic CD34 þ 38À cells in the presence of ABCG2 inhibition, conferred by other drug transporters, among which are ABCB1 and ABCC1.
Together, the findings argue that selective modulation of ABCB1 or ABCG2 is not sufficient to circumvent resistance of leukemic CD34 þ 38À cells. Simultaneous modulation of several transporters, among which are ABCB1 and ABCG2, could be required to sufficiently increase drug accumulation and eradicate CD34 þ 38À stem cells in AML. The report of improved clinical outcome in a trial using cyclosporine as a P-glycoprotein inhibitor in AML, 68 in contrast to the other poor results of selective ABCB1 modulation on long-term disease outcome, could be in line with this assumption since cyclosporine is a more promiscuous ABC-transporter inhibitor with effects on both ABCB1 and ABCG2. 69 Other ABC transporters involved in the drug resistance of leukemic stem cells
In the effort to profile gene expression patterns of all transmembrane ABC transporters in normal and leukemic CD34 þ 38À hematopoietic cells, it was found that the ABCtransporter gene expression profile of CD34 þ 38À cells was largely conserved in AML. 25 Thirty-eight transporters were expressed in leukemic CD34 þ 38À cells, including all members currently associated with drug resistance (Table 1 and Ross  and Doyle   24 ), many in differential manner in comparison to CD34 þ 38 þ leukemic cells. The data suggest that drug-effluxmediated drug resistance of leukemic stem cells may be conferred by many members of the ABC family of membrane transporters with possibly promiscuous action on different chemotherapeutical compounds. The conserved expression of many members of the ABCA family and their emerging role in drug resistance 70 could be of particular importance in this regard and warrants future investigations to further elucidate the role of this class of transporters in drug resistance.
ABC transporters in CML stem cells and their role in imatinib resistance
CML is a disease originating from C34 þ 38À HSCs. 56 Treatment with the tyrosine kinase inhibitor imatinib has drastically improved the outcome in patients suffering from this disease, but molecular persistence of BCR-ABL transcripts during therapy is a frequent finding and the discontinuation of the drug frequently leads to relapse of the disease, suggesting that CML stem cells survive treatment with this agent. 71 The role of ABC transporters in CML stem cell resistance has been the topic of an increasing number of studies in the past 4 years.
Several studies have reported ABCB1-mediated imatinib resistance through active efflux of the compound in vitro.
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Imatinib resistance was reported in K562/Dox cells, which could be reversed by the ABCB1 inhibitors verapamil and PSC-833. 73 Retroviral overexpression of ABCB1 similarly induced verapamil reversible resistance to imatinib. These results were confirmed in a study demonstrating that imatinib levels decrease in ABCB1 expressing K562 cells with loss of the effect on cellular proliferation and apoptosis 74 and the observation that ABCB1-mediated resistance to imatinib could be reversed by transposon-based knockdown of ABCB1 in these cells. 75 Although, in contrast, it has also been reported that retroviral overexpression of Pgp in K562 cells does not confer resistance to imatinib, 76 the majority of evidence supports a role of ABCB1 in resistance against imatinib in vitro.
It is, however, unclear what the contribution of these transporters is to the resistance of CML stem cells and hence whether they influence patient's response to imatinib. A recent report on an in vivo murine transplantation model of CML-like myeloproliferative disease using Mdr1a/1b-null mice displayed similar responses to imatinib to wild-type mice and an unchanged incidence and latency of disease transplanted from imatinib-treated mice in secondary recipients arguing that Mdr1 does not contribute to stem cell imatinib resistance in this model. 77 Additionally, levels of ABC transporters ABCA2, ABCG2 and ABCB1 in CML patients were not correlated with response to imatinib. 78 These combined data suggest that, similar to the situation in AML, redundant transporters and other (innate) resistance mechanisms 79 are likely to confer additional resistance to this agent in leukemic stem cells. Of note, K562 cells have been derived from a CML patient entering blast crisis in which the stem cell compartment shifts to the granulocytemonocyte progenitor population, 80 a compartment that normally lacks the ability for self-renewal and in which its innate stem cell resistance mechanisms, including many ABC transporters, may not be present, providing a possible explanation for the apparent discrepancy between in vitro and in vivo observations.
Whether the redundant imatinib-resistance mechanisms in CML stem cells include ABCG2-mediated imatinib efflux has been a matter of debate. Imatinib has been reported to be effluxed by ABCG2 81 and its bioavailability and pharmacokinetics are influenced by ABCG2. 82 In contrast, ABCG2 was reported as an inhibitor rather than substrate in an osteosarcoma cell line with no effect on intracellular imatinib accumulation or resistance. 83 The first evidence that ABCG2 mediates imatinib resistance was described in transduced K562 cells 84 with the interesting observation that ABCG2 was downregulated at the post-transcriptional level by imatinib-mediated inhibition of BCR-ABL through the PI3K-Akt pathway. The effect of BCR-ABL signaling on ABCG2 expression was later substantiated by the observation of functional overexpression of ABCG2 in primary CD34 þ CML cells, 85 but in these cells inhibition of ABCG2 by FTC had no effect on drug accumulation or sensitivity to imatinib, although imatinib was able to inhibit ABCG2-mediated mitoxantrone efflux. The combined results again suggest the presence of redundant imatinib resistance mechanisms in primary leukemic CD34 þ cells bypassing the ABCG2-mediated imatinib efflux and resistance. This is similar to the situation in AML stem cells where ABCG2 has only a minor effect on drug accumulation and inhibition of ABCG2 does not lead to increased cytotoxicity, due to the presence of redundant (partly drug efflux mediated) resistance mechanisms. 65 Together, the current knowledge may temper expectations about the efficacy of ABCB1 or ABCG2 inhibition as a strategy to eradicate CML stem cells in chronic phase of the disease.
ABC-transporter modulation in leukemia: A leukemic stem cell 'sensitizing' strategy?
The strong prognostic value of ABCB1 [86] [87] [88] has led to the introduction of ABCB1 modulators in the treatment of AML in an attempt to circumvent drug resistance by targeting ABCB1-mediated drug efflux in leukemic blasts. Although initial trials, by using the agents with pleiotropic effects on drug resistance (quinine and cyclosporine), showed promising results with increased complete remission (CR) and overall survival (OS) in some trials, 68 subsequent trials with the agents with increased specificity and potency of ABCB1 inhibition (PSC-833) have shown consistently poor results with no effect on overall survival and increased toxicity. 64, 89, 90 In interpreting these disappointing results, from the novel paradigm of treating leukemia by eradicating the leukemia stem cell population, it will be important to answer the following questions:
1. Is ABCB1 modulation an effective strategy to eradicate leukemic stem cells?
Extrapolating the available in vitro data, it seems unlikely that modulation of a single drug efflux mechanism, such as ABCB1 or ABCG2, will result in sufficient increase in drug accumulation, circumvent drug resistance and eventually eradicate this leukemic stem cell population. Additionally, in this context, it has to be realized that drug extrusion is only one way of cancer cells to evade chemotoxicity. Many other mechanisms are active and it is reasonable to assume that these mechanisms, in parallel to ABC transporters, preferentially protect the long-lived HSCs and their malignant counterparts.
2. Is ABCB1 modulation a leukemia-specific targeting therapy?
Several reports suggest that ABCB1-mediated drug efflux is decreased in primitive leukemic cells in comparison to their normal counterparts and as such identifies a population of residual normal stem cells in AML. Although reduced ABCB1 expression and function in leukemic CD34 þ 38À cells in comparison to their normal counterparts may reflect altered differentiation status of these cells and does not necessarily apply to 'true' leukemic stem cells, these findings suggest that ABCB1 modulation is not a leukemia-specific targeted therapy and, in fact, may preferentially target normal rather than leukemic stem cells. Additionally, ABCB1 modulation targets its physiological role in many other tissues especially those involved in drug detoxification. Anticipated toxicity has led to dose reduction of chemotherapeutical agents in the ABCB1 modulation arm of clinical trials, which may have attributed to the lack of clinical benefit.
The negative answers to both questions challenge the rationale for the use of ABCB1 modulation as a strategy to target leukemic stem cells in AML, and have to be taken into account when interpreting the disappointing results from clinical trials showing no benefit of ABCB1 modulation at the cost of increased toxicity. The clinical observation that ABCB1 modulation has not resulted in increased overall and relapse free survival in AML, as would be anticipated if ABC-drug-transport inhibitors function as 'leukemia stem cell-sensitizing agent' that kill the leukemia-initiating cell population, seems congruent with the laboratory findings described.
3. Does challenging the role of ABCB1 in drug resistance of leukemic stem cells dismiss the value of ABCB1 as a prognostic marker in AML, one of the hallmark rationales for ABCB1 modulation in this disease?
It is conceivable that expression and activity of ABCB1 is a pleiotropic marker of prognosis; it may be a marker of immature (CD34 þ 38À) leukemia 91 as suggested by the high expression of ABCB1 in CD34 þ 38À cells. These cells are likely characterized by the conserved function of other innate drug resistance and anti-apoptotic mechanisms that protect primitive progenitor cells, including many drug-resistance-related ABC transporters as reviewed in the previous chapters. The prognostic value of ABCB1 may reflect the innate drug resistance conferred by these associated drug resistance and anti-apoptotic mechanisms, rather than functional activity of a single drug extrusion mechanism. The observations that ABCB1 is not upregulated at relapse and that ABCB1-related clonal selection does not occur after failure of standard therapy 92 are congruent with these alternative explanations of the prognostic value of ABCB1 in AML.
The observation that drug efflux in leukemic CD34 þ 38À cells is conferred by the simultaneous action of several redundant transport mechanisms suggests that the use of broad-spectrum inhibitors for ABC transporter modulation is required for the eradication leukemic stem cells rather than the modulation of single efflux mechanisms. However, the strategy of broad-spectrum modulation of ABC transporters is likely to encounter enhanced hematological toxicity since the expression of most of these transporters in leukemic stem cells represents a conserved physiological function of normal HSCs. Although enhanced hematological toxicity could be managed in a transplant setting, additionally, nonhematological toxicity is anticipated since many of these transporters serve important functions in detoxification processes. Finally, it remains important to realize that ABC transporters are only a player in the wide spectrum of drug resistance in cancer stem cells. These long-lived cells are likely to be naturally resistant to chemotherapy through their quiescence, precluding efficacy of drugs that target either the cell cycle or rapidly dividing cells, their capacity for DNA repair and reluctance to enter apoptosis. Tackling drug resistance in cancer requires ongoing research into all mechanisms of drug resistance, which should continue focusing on the cancer stem cell to offer future patients an increasing change on cure from this disease.
Role of ABC transporters in the pathogenesis of malignant HSC disorders? Perspectives for their utility as therapeutical targets ABC transporters are evolutionary extremely well conserved and their role in the protection of stem cells against xenobiotic insults is well documented for some members (ABCB1, ABCC1 and ABCG2). Given the important role of xenobiotic and chemotherapeutical exposure in some forms of cancer including (secondary) leukemia, it is conceivable that impaired xenobiotic transport in tissue stem cells that are the target for malignant transformation attributes to increased susceptibility for progression-associated genetic events induced by these genotoxic xenobiotics. In this context, it is noteworthy that significantly reduced gene expression and function of ABCB1 has been described in leukemic CD34 þ (38À) cells in comparison to their normal counterparts in AML 50, 61 and aplastic anemia, 93 a hematopoietic disorder associated with xenobiotic exposure and considered a prominent risk factor for the development of clonal hematopoietic disorders with about 25% of patients developing acute leukemia. 94 It remains to be determined whether aberrant expression and function in these reports reflects primary differences of gene expression or secondary effects of transformation but polymorphisms in the ABCB1 gene, associated with reduced expression and function of ABCB1, have been related to the occurrence of acute leukemia 95 and other tumors 96 in some studies. To date, despite combined administration of xenobiotic/chemotherapeutical agents and ABCB1 modulators, increased incidence of secondary hematological or solid tumors has not been reported, which may reflect the other side of the two-edged sword that stem cells are protected by redundant mechanisms, preventing both therapeutical and detrimental effects of transporter modulation.
As reviewed herein, a putative physiological function of ABC transporters in HSCs is their role in maintaining cell quiescence by preventing differentiation. The increasing recognition that cancer originates from normal stem cells and that molecules involved in cell fate decisions and differentiation of stem cells have a key role in carcinogenesis prompts further investigations in this direction. ABC transporters gene profiling in leukemic stem cells has identified many ABC transporters not previously associated with stem cell biology that may be involved in such functions as detailed in this review. Although expression patterns were generally well conserved after malignant transformation, heterogeneity, both in frequency and level of expression, occurred for a subset of transporters, among which were the members of the ABCA family. This may be of particular importance given their putative involvement in the transmembrane transport of endogenous lipid substrates such as phospholipids and essential fatty acids, substrates involved in the regulation of differentiation of hematopoietic cells. Whether these aberrant expression patterns reflect differences in differ-entiation state of leukemic and normal stem cells or are directly involved in the differentiation failure of HSC in leukemia, however, is currently unknown. Besides determining the role of ABC transporters in drug resistance of cancer stem cells, a challenge for future research will be the elucidation of the physiological function of these molecules in human normal and malignant stem cells. Ultimately, elucidation of the role of ABC transporters in stem cell biology and malignant hematopoiesis may provide targets for stem cell manipulation in leukemia independent of their role in drug resistance.
